RGBP News $RGBP Regen BioPharma Provides Updat
Post# of 373
Regen BioPharma Provides Update on HemaXellerate IND Progress After Conference Call With FDA
Marketwire - 4 mins ago
Regen BioPharma Inc. (OTCBB: RGBP) announced today the outcome of a telephonic meeting with the FDA regarding IND #15376 for use of HemaXellerate in the treatment of aplastic anemia. The subject of this meeting with FDA cell therapy experts was the Company's existing experimental data and the requirement for additional safety data with regard to the IND application.